Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Cosmo appoints New CSO as current CSO retires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/26/2019 | 01:05am EST

Cosmo appoints New CSO

as current CSO retires

Dublin, Ireland - November 26, 2019 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today announced that Luigi Moro, its Chief Scientific Officer, is retiring and that Roberto Camerini MD will assume his responsibilities as of January 1, 2020.

Luigi Moro joined Cosmo in 1999 after a long career in drug development in Farmitalia Carlo Erba, Recordati and Poli Industria Chimica. He led the development of all approved Cosmo products to date, namely Lialda, Uceris, Eleview and Aemcolo; and he also led the development of all Cassiopea products to date. Mr. Moro will continue making his services available as a consultant to Cosmo and will continue being the CSO of Cassiopea.

Roberto Camerini MD joined Cosmo in December 2018. He was formerly Director of Pre-Clinical and Clinical Research and Development at Alfa Wassermann S.p.A. from 2015 to 2018, and Head of Corporate Clinical Research at Sigma Tau S.p.A. Previously he worked for Serono and Abbot.

Mauro Ajani, Executive Chairman of Cosmo said: "I recruited Luigi when we were but a handful of people. His expertise contributed in an essential fashion to the transformation of Cosmo from a small contract drug manufacturer to a listed specialty pharma company and I will be forever thankful for that. It is great that he is willing to continue making his experience available to the Company. We believe we have found in Roberto Camerini the right successor to lead our product development".




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COSMO PHARMACEUTICALS N.V.
01/22COSMO PHARMACEUTICALS N : Methylene Blue MMX regulatory update Substantial align..
AQ
01/21COSMO PHARMACEUTICALS METHYLENE BLUE : Substantial alignment reached with FDA on..
TE
01/13Acacia Pharma enters into strategic in-licensing, investment and loan transac..
AQ
01/13Cosmo sub-licenses its ByFavo US rights to Acacia Pharma, takes an initial 14..
AQ
01/10Boeing faces fresh scandal
01/10Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma..
TE
2019RedHill Biopharma Initiates U.S. Promotion of Aemcolo for Travelers' Diarrhea
AQ
2019COSMO PHARMACEUTICALS N : announces worldwide exclusive Distribution Agreement f..
AQ
2019Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement fo..
TE
2019COSMO PHARMACEUTICALS N : appoints New CSO; as current CSO retires
PU
More news
Financials (EUR)
Sales 2019 47,1 M
EBIT 2019 -17,4 M
Net income 2019 -27,6 M
Finance 2019 119 M
Yield 2019 -
P/E ratio 2019 -40,5x
P/E ratio 2020 -125x
EV / Sales2019 20,6x
EV / Sales2020 12,0x
Capitalization 1 090 M
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 100,04  €
Last Close Price 74,53  €
Spread / Highest target 73,7%
Spread / Average Target 34,2%
Spread / Lowest Target -2,86%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.4.17%1 203
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG3.03%284 454
PFIZER1.63%220 369
MERCK AND COMPANY-5.46%218 904
NOVARTIS-0.38%213 484